Labs / Assays & in vitro testing
Probiocdmo
Nanjing, China · probiocdmo.com
GMP
ProBio is a global CRDMO that provides discovery, development, and manufacturing services for biologics, cell and gene therapy, mRNA, plasmid DNA, viral vectors, and in vivo CAR-T programs. It serves biotech and pharmaceutical companies from sites in the United States, China, the Netherlands, and South Korea, with U.S. operations in New Jersey.
They take quote requests by email.
What they offer
Therapeutic antibody discovery
Provides target discovery, lead generation, lead optimization, in vitro bioassays, in vivo validation, and developability assessment for antibody programs.
Monoclonal and bispecific antibody development
Supports discovery, cell line development, process optimization, characterization, validation, and GMP manufacturing for monoclonal and bispecific antibodies.
ADC discovery and development
Delivers antibody discovery, payload-linker selection, conjugation optimization, bioassays, pharmacology, and IND-enabling CMC for antibody-drug conjugates.
In vivo CAR-T development
Supports discovery through IND-enabling CMC for in vivo CAR-T using plasmid, antibody, mRNA-LNP, and targeted lentiviral vector platforms.
mRNA vaccine development and manufacturing
Provides plasmid DNA production, IVT-mRNA manufacturing, LNP encapsulation, analytical testing, GMP production, and fill-finish services.
Plasmid DNA services
Offers plasmid-related services for CGT and vaccine programs, including linearized DNA manufacturing and plasmid CMC support.
Viral vector services
Provides lentiviral vector development, packaging, concentration, purification, and GMP manufacturing support.
Cell and gene therapy CMC services
Supports cell banking, process development, characterization, validation, analytical development, and stability studies for CGT programs.
What they work on
- Modalities
- Antibody, Bispecific, ADC, mRNA, Viral vector, Cell therapy, Vaccine, Plasmid DNA, LNP / formulation
- Species and models
- HEK293T cells, CHO-K1, hybridoma, single B cell screening, phage display
- Assays and studies
- in vitro bioassays, cell-based bioassays, developability assessment, bioanalytical development, analytical testing, pharmacology studies, efficacy and safety evaluation, internalization bioassay, cytotoxicity assay, bystander effect study, pharmacodynamics, pharmacokinetics, and 1 more
- Instruments and platforms
- SEC-HPLC, HIC-HPLC
- Scale and capacity
- 2000L drug substance manufacturing, 50-2000 L GMP manufacturing, GMP biologics manufacturing facility in New Jersey
- Therapeutic areas
- oncology, autoimmune diseases, infectious disease, genetic medicine
- Turnaround
- PCC in as little as 6 months · DNA to tox batch in 4 months · CLD: DNA to 6 top clones in 10 weeks · 3–5 months · 5–6 months · 7–9 months
- What to send
- Target and mechanism of action information · DNA for cell line development and CMC workflows
- Type
- CRDMO
- Sites
- Hopewell, New Jersey, United States · Nanjing, China · Hong Kong, China · Shanghai, China · the Netherlands, Netherlands · South Korea, South Korea
- Quality
- FDA (Phase-appropriate compliance; GMP capacity meeting regulatory requirements) · EMA (Phase-appropriate compliance; GMP capacity meeting regulatory requirements) · NMPA (Phase-appropriate compliance; GMP capacity meeting regulatory requirements)
- Serves
- United States, Europe, Asia Pacific, EMEA
Similar labs. Sparx BIO, Evotec, Aurigene Pharmaceutical Services, 3C Therapeutics
Found in a contract services directory. Listing built from probiocdmo.com. Work here? Claim this listing.